Usa virus covid-19 vaccine Government Usa

Altimmune partners with DynPort on intranasal Covid-19 vaccine

Reading now: 464
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Biopharmaceutical firm Altimmune has signed a teaming agreement with DynPort Vaccine to support US Government funding efforts for the development of its intranasal Covid-19 vaccine candidate, AdCOVID.

If successful, the partnership will be extended to programme management, drug development and regulatory support for the vaccine product.

DynPort has expertise in vaccine development and the preclinical, manufacturing, clinical and regulatory activities required for FDA licensure of new drug products.

Altimmune expects that the collaboration with DynPort will boost its capabilities to obtain and execute on US Government funding.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA